#
##
##
|||||Page|
|---|---|---|---|---|
|Reference and administrative||details ofthe Company,|its Trustees and advisers||
|Trustees'
report||||2-5|
|Independent|auditors'
report|on the financial statements||6-9|
|Consolidated|statement
offinancial activities|||10|
|Consolidated|balance sheet|||11 - 12|
|Company
balance sheet||||13-14|
|Consolidated|statement
ofcash flows|||15|
|Notes to the|financial statements|||16-34|
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
|||||Unrestricted|Restricted|Total|Total|
|---|---|---|---|---|---|---|---|
|||||funds|funds|funds|funds|
|||||2022|2022|2022|2021|
||||Note|5||||
|Income from:||||||||
|Donations
and legacies|||||||1,520|
|Other trading|activities|||1,266,209||1,266,209|1,177,061|
|Investments|||||15|15|119|
|Other income||||3,928||3,928|73,596|
|Total income||||1,270,137|15|1,270,152|1,252,296|
|Expenditure
on:||||||||
|Raising funds|||7|910,254|500|910,754|917,037|
|Charitable
activities|||6|390||390|6,920|
|Total expenditure||||910,644|500|911,144|923,957|
|Net movement|in funds|||359,493|(485)|359,008|328,339|
|Reconciliation|offunds:|||||||
|Total funds brought||forward||3,910,863|63,608|3,974,471|3,646,132|
|Net movement|in funds|||359,493|(485)|359,008|328,339|
|Total funds carried||forward||4,270,356|63,123|4,333,479|3,974,471|
##
##
##
##
||COMPANY BALANCE SHEET|COMPANY BALANCE SHEET|||
|---|---|---|---|---|
||ASAT 31 MARCH 2022||||
||Note|2022f||2021f|
|Fixed assets|||||
|Tangible assets|13|12,870||12,870|
|Investments|14|4,202,292||3,840,149|
|||4,215,162||3,853,019|
|Current assets|||||
|Debtors|16|43,040|45,799||
|Cash at bank and|in hand|75,308|82,529||
|||118,348|128,328||
|Creditors: amounts|falling due within one||||
|year|17|(30)|(6,875)||
|Net current assets||118,318||121,453|
|Total net assets||4,333,480||3974472|
|Charity funds|||||
|Restricted funds|19|63,123||63,608|
|Unrestricted
funds|19|4,270,357||3,910,864|
|Total funds||4,333,480||3,974,472|
##
##
||||||2022|2021|
|---|---|---|---|---|---|---|
|Cash flows from operating|activities||||||
|Net cash used
in operating|activities||||500,666|488,079|
|Cash flows from investing|activities||||||
|Interest receivable|||||(15)|(119)|
|Purchase oftangible
fixed assets|||||(23,605)|(5,814)|
|Net cash used in investing|activities||||(23,620)|(5,933)|
|Cash flows from financing|activities||||||
|Net cash provided
by financing
activities|||||||
|Change
in cash and cash|equivalents|in|the year||477,046|482,146|
|Cash and cash equivalents|at the beginning||ofthe year||573,004|90,858|
|Cash and cash equivalents|at the end|of|the year||1,050,050|573,004|
|The notes on pages 16to 34form part ofthese financial||||statements|||
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
|Charity trading|income|
|---|---|
|Total 2021||
|Unrestricted|Total|Total|
|---|---|---|
|funds|funds|funds|
|2022f|2022
F|2021f|
|1,266,209|1,266,209|1,177,061|
|1,177,061|1,177,061||
##
|Restricted|Total|Total|
|---|---|---|
|funds|funds|funds|
|2022f|2022f|2021f|
|15|15|119|
|119|119||
##
|||Unrestricted|Total|Total|
|---|---|---|---|---|
|||funds|funds|funds|
|||2022|2022|2021|
|||6|6||
|Government|grants receivable|3,928|3,928|60,596|
|Other income||||13,000|
|||3,928|3,928|73,596|
|Total 2021||73,596|73,596||
##
##
##
|||Unrestricted|Total|Total|
|---|---|---|---|---|
|||funds|funds|funds|
|||2022f|2022f|2021|
|Cost ofsales and administrative|expenses|798,634|798,634|797,413|
|Depreciation||111,620|111,620|119,275|
|||910,254|910,254|916,688|
|Total 2021||916,688|916,688||
##
##
##
|||Unrestricted|Restricted|||
|---|---|---|---|---|---|
|||funds|funds|Total|Total|
|||2022f|2022f|2022|2021f|
|General|fund|390||390|6,420|
|Basingstoke Breast Cancer self help group|||||500|
|||390||390|6,920|
|Total 2021||6,420|500|6,920||
##
||||||||Grant||||
|---|---|---|---|---|---|---|---|---|---|---|
||||||||funding
of|Support|Total|Total|
||||||||activities|costs|funds|funds|
||||||||2022f|2022|2022
Z|2021f|
|General|fund|||||||390|390|6,420|
|Basingstoke||Breast|Cancer|self|help|group||||500|
|||||||||390|390|6,920|
|Total2021|||||||500|6,420|6,920||
##
##
##
##
|||||2022
6|2021f|
|---|---|---|---|---|---|
|Fees payable to the Company's||auditor|for the audit ofthe Company's|||
|annual accounts||||5,555|5,546|
|Fees payable to the Company's||auditor|in respect of:|||
|Audit ofthe subsidiary|annual|accounts||5,370|5,530|
|All non-audit
services|not included
above|||680|646|
##
|||||Group|Group|
|---|---|---|---|---|---|
|||||2022
6|2021
f|
|Wages and|salaries|||328,386|390,675|
|Social security costs||||27,138|35,426|
|Contribution|to defined|contribution|pension schemes|5,757|9,056|
|||||361,281|435,357|
|||||||||Group|Group|
|---|---|---|---|---|---|---|---|---|---|
|||||||||2022|2021|
|Employees||||||||13|16|
|The|number|of Group|employees|whose|employee|benefits|(excluding|employer
pension|costs)|
|exceeded 660,000was:||||||||||
|||||||||Group|Group|
|||||||||2022|2021|
|In the|band f70,001 - 680,000|||||||1|f|
##
##
##
##
||Long-term|Plant,||
|---|---|---|---|
||leasehold|machinery
&||
||ProPerty|fixtures|Total|
||6|6||
|Cost or valuation||||
|At 1 April 2021|4,403,885|1,573,878|5,977,763|
|Additions||23,605|23,605|
|At 31 March 2022|4,403,885|1,597,483|6,001,368|
|Depreciation||||
|At 1 April 2021|1,170,910|1,342,031|2,512,941|
|Charge for the year|38,936|72,687|111,623|
|At 31 March 2022|1,209,846|1,414,718|2,624,564|
|Net book value||||
|At 31 March 2022|3,194,039|182,765|3,376,804|
|At 31March 2021|3,232,975|231,847|3,464,822|
##
##
##
##
||Fixtures,|
|---|---|
||fittings &|
||equipment|
||E|
|Cost or valuation||
|At I April 2021|13,350|
|At 31 March 2022|13,350|
|Depreciation||
|At 1 April 2021|480|
|At 31 March 2022|480|
|Net book value||
|At 31 March 2022|12,870|
|At 31March 2021|12,870|
##
##
||Investments|
|---|---|
||In|
||subsidiary|
||company|
|Company|6|
|Cost or valuation||
|At 1 April 2021|5,733,969|
|At 31 March 2022|5,733,969|
|Impairment||
|At 1 April 2021|1,893,820|
|Reversal ofimpairments|(362,143)|
|At 31 March 2022|1,531,677|
|Net book value||
|At 31 March 2022|4,202,292|
|At 31March 2021|3,840,149|
##
##
##
|Name|||Company|Registered|office or principal|Principal activity|Principal activity|Principal activity|
|---|---|---|---|---|---|---|---|---|
||||number|place ofbusiness|||||
|The Ark Conference||Centre|03683701|Dinwoodie|Drive, Basingstoke,|Provision ofa facility|||
|Limited||||Hampshire,|RG24 9NN|for conferencing||and|
|||||||training|in the field of||
|||||||medicine|||
|Class of|Holding|Included|in||||||
|shares||consolidation|||||||
|Ordinary|100% Yes||||||||
||The financial
results|ofthe subsidiary
for|the year were:||||
|---|---|---|---|---|---|---|
||Name||Income|Expenditure|Profit for|Net assets|
||||5|8|the year|5|
||||||E||
||The Ark Conference|Centre Limited|1,272,397|(910,254)|362,143|4,202,293|
|15.|Stocks||||||
||||||Group|Group|
||||||2022
5|2021
f|
||Finished goods and|goods for resale|||10,520|8,847|
##
##
##
|||Group|Group|Company|Company|
|---|---|---|---|---|---|
|||2022f|2021f|2022f|2021f|
|Due within one year||||||
|Trade debtors||10,386|5,944|||
|Other debtors||4,779|3,809|||
|Prepayments|and accrued income|18,400|15,851|43,040|45,799|
|||33,565|25,604|43,040|45,799|
##
||||Group|Group|Company|Company|
|---|---|---|---|---|---|---|
||||2022f|2021|2022f|2021|
|Trade creditors|||31,931|23,099|||
|Other taxation|and social security||8,016|9,145|||
|Other creditors|||1,290|1,490|||
|Acciuals and deferred||income|96,223|64,071|30|6,875|
||||137,460|97,805|30|6,875|
##
##
|Group|Group|
|---|---|
|2022f|2021f|
##
##
##
##
|Statemen|t o|ffunds - current year|||||
|---|---|---|---|---|---|---|
|||||||Balance at|
||||Balance at 1|||31 March|
||||April 2021|Income|Expenditure|2022|
||||6|E|8||
|Unrestricted||funds|||||
|Reserves|||3,910,863|1,270,137|(910,644)|4,270,356|
|Restricted funds|||||||
|Training|fund||63,108|15||63,123|
|Basingstoke||Breast Cancer self-help group|500||(500)||
||||63,608|15|(500)|63,123|
|Total offunds|||3,974,471|1,270,152|(911,144)|4,333,479|
##
##
##
|Statement of|funds
-prior year||||||
|---|---|---|---|---|---|---|
|||||||Balance at|
||||Balance al|||31March|
||||1 April 2020
f|Income
f|Expenditure|2021
f|
|Unrestricted|funds||||||
|Reserves|||3,583,'I43|'1,251,177|(923,457)|3,910,863|
|Restricted funds|||||||
|Training
fund|||62,989|'I19||63,108|
|Basingsioke Breast Cancer self-help||group||1,000|(500)|500|
||||62,989|1,119|(500)|63,608|
|Total offunds|||3,646,132|1,252,296|(923,957)|3,974,471|
##
##
||||||Balance at|
|---|---|---|---|---|---|
|||Balance at 1|||31 March|
|||Apri I2021f|Income
f|Expenditure
f|2022f|
|General funds||3,910,863|1,270,137|(910,644)|4,270,356|
|Restricted|funds|63,608|15|(500)|63,123|
|||3,974,471|1,270,152|(911,144)|4,333,479|
##
##
##
##
|Summar|y
offunds - prior year|||||
|---|---|---|---|---|---|
||||||Balance at|
|||Balance at|||31March|
|||1April 2020|Income|Expenditure|2021f|
|General|funds|3,583,143|1,251,177|(923,457)|3,910,863|
|Restricted funds||62,989|1,119|(500)|63,608|
|||3,646,132|1,252,296|(923,957)|3,974,471|
##
##
|Analysis|of n|et ass|ets|between funds - curr|ent year|||
|---|---|---|---|---|---|---|---|
||||||Unrestricted|Restricted|Total|
||||||funds|funds|funds|
||||||2022|2022|2022|
||||||6|6|6|
|Tangible|fixed|assets|||3,376,804||3,376,804|
|Current|assets||||1,031,012|63,123|1,094,135|
|Creditors|due|within|one|year|(137,460)||(137,460)|
|Total|||||4,270,356|63,123|4,333,479|
##
##
##
|Analysis|of n|et assets between funds
-prior y|ear|||
|---|---|---|---|---|---|
||||Unrestricted|Restricted|Total|
||||funds|funds|funds|
||||2021|2021|2021|
||||5||5|
|Tangible|fixed|assets|3,464,822||3,464,822|
|Current|assets||543,347|64,108|607,455|
|Creditors|due|within one year|(97,305)|(500)|(97,805)|
|Creditors|due|in more than one year|(1)||(1)|
|Tl|||3,910,863|63,608|3,974,471|
##
|||2022|2021f|
|---|---|---|---|
|Total reserves||4,333,479|3,974,471|
|Restricted|reserves|(63,123)|(63,608)|
|Designated|reserves|||
|Net book value offixed assets||(3,376,804)|(3,464,822)|
|||893,552|446,041|
##
##
|||||||||Group|Group|
|---|---|---|---|---|---|---|---|---|---|
|||||||||2022f|2021f|
||Net income for the year (as per Statement of||||Financial|Activities)||359,008|328,339|
||Adjustments
for:|||||||||
||Depreciation
charges|||||||111,623|119,275|
||Interest receivable|||||||15|119|
||Increase
in stocks|||||||(1,673)|(1,478)|
||Decrease/(increase)|in debtors||||||('7,961)|308,621|
||Increase/(decrease)|in creditors||||||39,654|(286,797)|
||Net cash provided
by operating|||activities||||500,666|488,079|
|24.|Analysis ofcash and||cash equivalents|||||||
|||||||||Group|Group|
|||||||||2022f|2021f|
||Cash
in hand|||||||1,050,050|573,004|
||Total cash and cash||equivalents|||||1,050,050|573,004|
|25.|Analysis ofchanges||in net debt|||||||
|||||||||Other non-||
||||||At 1 April|||cash|At 31 March|
|||||||2021
f|Cash flows
f|changes|2022f|
||Cash at bank and in hand||||573,004||477,046||1,050,050|
||Debt due after 1 year|||||(1)||1||
||||||573,003||477,046|1|1,050,050|
##
##
##
##
||||Group|Group|
|---|---|---|---|---|
||||2022|2021|
|Not later than||1 year|15,871|13,557|
|Later than|1 year and not later than 5years||14,809|22,808|
||||30,680|36,365|
##